“Global Laboratory Information Systems market set to grow to $2.8bn by 2023” says new Visiongain report

19 November 2018
Pharma

Visiongain has launched a new pharma report:Laboratory Information Systems Market Report: Web-Based, On-Premise Based, Cloud-Based, Software, Hardware, Services, Clinical, Drug Discovery, Industrial.

The laboratory information system ("LIS") industry includes set of programs and hardware, which are part of an integrated system designed for healthcare information. It is an information system intended for capturing complex data and information related to medical and industrial laboratories, including clinical and analytical laboratories. The information system interfaces with analytical instruments and allows users to obtain, store, manage, retrieve and record laboratory data. As industrial and medical laboratories are diverse with different requirements; hence, there is no standard information system designed for laboratories. Therefore, a laboratory information system is customized, developed, and configured according to the requirements of a laboratory.

The lead analyst of the report commented "The global LIS market is currently fragmented in most countries, but few large vendors hold significant market shares. However, many new players are entering the market and the consolidation of small players with larger counterparts is shaping the vendor landscape. Competition is getting intense and key players are trying to sustain themselves by improving their delivery models with increased usage of technology."

Leading companies featured in the report include Abbott Laboratories, Cerner Corporation, Eclipsys Corporation, LabVantage Solutions, Inc., LabWare, Inc., McKesson Corporation, Medical Information Technology, Inc., Thermo Fisher Scientific

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever